96 POSTER A population pharmacokinetic model for BIBF 1120, a triple angiokinase inhibitor, in cancer patients after single and multiple oral dosing

P.Stopfer; R.Kaiser; N.Snelder; B.Ploeger; A.Staab

首页> 外文期刊>European Journal of Cancer Supplements >96 POSTER A population pharmacokinetic model for BIBF 1120, a triple angiokinase inhibitor, in cancer patients after single and multiple oral dosing

【24h】

96 POSTER A population pharmacokinetic model for BIBF 1120, a triple angiokinase inhibitor, in cancer patients after single and multiple oral dosing

机译：96 POSTER在癌症患者中，单次和多次口服给药后，BIBF 1120（一种三联血管激酶抑制剂）的总体药代动力学模型

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements 》 |2006年第12期| 共1页
作者
P.Stopfer; R.Kaiser; N.Snelder; B.Ploeger; A.Staab;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学 ;
关键词

相似文献

外文文献
中文文献
专利

1. 73 POSTER Pharmacokinetic characterization of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) in advanced cancer patients [J] . P.Stopfer, W.Roth, K.Mross, European Journal of Cancer Supplements . 2006 ,第12期

机译：73 POSTER口服活性三联血管激酶抑制剂（VEGFR，PDGFR，FGFR）在晚期癌症患者中的药动学特征
2. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. [J] . Reck M, Kaiser R, Eschbach C, Annals of oncology: official journal of the European Society for Medical Oncology . 2011 ,第6期

机译：II期双盲研究旨在研究两剂三联血管激酶抑制剂BIBF 1120在复发性晚期非小细胞肺癌患者中的疗效和安全性。
3. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120n in patients with relapsed advanced non-small-cell lung cancer [J] . J. von Pawel Annals of Oncology . 2011 ,第6期

机译：II期双盲研究，以研究两剂三联血管激酶抑制剂BIBF 1120n在复发性晚期非小细胞肺癌患者中的疗效和安全性
4. Evaluation of Pharmacokinetics of Meloxicam in the Rabbit after Single and Multiple Oral Doses [C] . Daniel V. Fredholm, James W. Carpenter, Butch KuKanich, Annual Conference and Expo of the Association of Avian Veterinarians . 2013

机译：单次口服剂量后兔美洛昔康药代动力学的评价
5. Clinical pharmacokinetic simulation/modeling as a tool for therapeutic drug monitoring and dose adjustment in special patient populations. [D] . Mohamed, Osama H. 2004

机译：临床药代动力学模拟/建模，作为特殊患者人群中治疗药物监测和剂量调整的工具。
6. BIBF 1120 (Nintedanib) a triple angiokinase inhibitor induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer [O] . Bercin Kutluk Cenik, Katherine T. Ostapoff, David E. Gerber, -1

机译：BIBF 1120（Nintedanib）是一种三联血管激酶抑制剂可诱导缺氧但不能引起EMT并阻止肺癌和胰腺癌的临床前模型发展
7. P3-091: A Phase I study of continuous oral treatment with the triple angiokinase inhibitor BIBF 1120 together with pemetrexed in previously treated patients with non-small cell lung cancer [O] . Hanna Nasser, Ellis Peter, Stopfer Peter, 2007

机译：P3-091：在先前治疗过的非小细胞肺癌患者中，使用三联血管激酶抑制剂BIBF 1120和培美曲塞连续口服治疗的I期研究

96 POSTER A population pharmacokinetic model for BIBF 1120, a triple angiokinase inhibitor, in cancer patients after single and multiple oral dosing

著录项

相似文献

相关主题

期刊订阅